Omnihealth Practice | APOLLO: Phase 3 randomized study of subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
Daratumumab and hyaluronidase-fihj (Darzalex Faspro) Drug Info
Daratumumab - wikidoc
Relapsed: D + PD Treatment | DARZALEX® IV (daratumumab)
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma | NEJM
Subcutaneous daratumumab plus pomalidomide-dexamethasone: an effective treatment option for MM - BJH
Daratumumab Re-Treatment Patterns. DPd: daratumumab, pomalidomide, and... | Download Scientific Diagram
Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials | Scientific Reports
British Journal of Haematology | Wiley Online Library
Pharmaceuticals | Free Full-Text | Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
Daratumumab Alone or in Combination with Lenalidomide/Dexamethasone or Pomalidomide/Dexamethasone for Relapsed/Refractory MM | Research To Practice
Impressive Results With Daratumumab Plus Lenalidomide/Dexamethasone in Multiple Myeloma - The ASCO Post
APOLLO Study | Int'l Myeloma Foundation
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment | Leukemia
Daratumumab regimen extends PFS among certain patients with relapsed or refractory myeloma
Subcutaneous daratumumab plus pomalidomide and dexamethasone in R/R MM - Medical Conferences
When and How to Treat Relapsed Multiple Myeloma | American Society of Clinical Oncology Educational Book
Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma - Transplantation ...
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma - Zhou - 2020 - Cancer Medicine - Wiley Online Library
Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients - ScienceDirect
The Evolving Clinical and Pharmacoeconomic Impact of Isatuximab in Multiple Myeloma Management | Value-Based Cancer Care
Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement - Justin R Arnall, Saad Z Usmani, Hawawu
Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma - Clinical Lymphoma, Myeloma and Leukemia
Suggested options for the treatment of relapsed multiple myeloma in... | Download Scientific Diagram
